Literature DB >> 21144734

Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies.

Lehendrick M Turner1, Joshua A Howard, Pouya Dehghanpour, Renée D Barrett, Neal Rebueno, Matthew Palmer, Sastry Vedam, Ann Klopp, Ritsuko Komaki, James W Welsh.   

Abstract

The pattern of failure is one of the major causes of mortality among thoracic patients. Studies have shown a correlation between local control and dose. Intensity-modulated radiation therapy (IMRT) has resulted in conformal dose distributions while limiting dose to normal tissue. However, thoracic malignancies treated with IMRT to highly conformal doses up to 70 Gy still have been found to fail. Thus, the need for dose escalation through simultaneous integrated boost (SIB) may prove effective in minimizing reoccurrences. For our study, 28 thoracic IMRT plans were reoptimized via dose escalation to the gross tumor volume (GTV) and planning target volume (PTV) of 79.2 Gy and 68.4 Gy, respectively. Reoccurrences in surrounding regions of microscopic disease are rare therefore, dose-escalating regional nodes (outside GTV) were not included. Hence, the need to edit GTV margins was acceptable for our retrospective study. A median dose escalation of approximately 15 Gy (64.8-79.2 Gy) via IMRT using SIB was deemed achievable with minimal percent differences received by critical structures compared with the original treatment plan. The target's mean doses were significantly increased based on p-value analysis, while the normal tissue structures were not significantly changed. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21144734     DOI: 10.1016/j.meddos.2010.09.007

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  6 in total

1.  Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities.

Authors:  Shervin M Shirvani; Jing Jiang; Daniel R Gomez; Joe Y Chang; Thomas A Buchholz; Benjamin D Smith
Journal:  Lung Cancer       Date:  2013-08-21       Impact factor: 5.705

2.  Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study.

Authors:  K Ji; L J Zhao; W S Liu; Z Y Liu; Z Y Yuan; Q S Pang; J Wang; P Wang
Journal:  Br J Radiol       Date:  2014-01-27       Impact factor: 3.039

3.  Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.

Authors:  Melenda D Jeter; Daniel Gomez; Quynh-Nhu Nguyen; Ritsuko Komaki; Xiaodong Zhang; Xiaorong Zhu; Michael O'Reilly; Frank V Fossella; Ting Xu; Xiong Wei; Hui Wang; Wenjuan Yang; Anne Tsao; Radhe Mohan; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-11-03       Impact factor: 7.038

4.  Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.

Authors:  Yujin Xu; Xiao Zheng; Xue Bai; Pu Li; Honglian Ma; Jin Wang; Xiao Hu; Ming Chen
Journal:  Oncotarget       Date:  2017-07-25

5.  [Application of Simultaneous Integrated Boost Intensity Modulated Radiotherapy in Locally Advanced Non-small Cell Lung Cancer].

Authors:  Jing You; Dan Yang; Dongming Li; Leilei Jiang; Rong Yu; Huiming Yu; Bo Xu; Weihu Wang; Anhui Shi
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-11-20

6.  Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.

Authors:  Qin Zhang; Xu-Wei Cai; Wen Feng; Wen Yu; Xiao-Long Fu
Journal:  BMC Cancer       Date:  2022-01-22       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.